A Trial to Find Out if REGN4336 is Safe and How Well it Works for Prostate Cancer
Phase 1/2
370
about 5.1 years
18+
Male only
13 sites in CA, CT, KY +8
What this study is about
This trial is testing a new drug called REGN4336, possibly with other drugs like cemiplimab or REGN5678. The goal is to see if REGN4336 is safe, how well it works, and what side effects might occur in people with advanced prostate cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cemiplimab
- 2.Take REGN4336
- 3.Take REGN5678
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cemiplimab, sarilumab
Primary: Incidence and severity of Immune-mediated Adverse Events (imAEs), Incidence and severity of Serious Adverse Events (SAEs), Incidence and severity of adverse event of special interest (AESIs), Incidence and severity of treatment-emergent adverse events (TEAEs), Incidence of dose-limiting toxicities (DLTs), Objective response rate (ORR) per modified per modified Prostate Cancer Working Group 3 (PCWG3) criteria
Secondary: Incidence and severity of SAEs, Incidence and severity of TEAEs, ORR per modified per modified PCWG3 criteria
Oncology